NSEGeneral Updates8 Oct 2026 · 8 Oct 2026, 07:22 pm
General Updates
Aarti Drugs Limited · AARTIDRUGS
✦ AI SummaryESG
Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating, which has assigned an Environmental, Social, and Governance (ESG) Rating of 'Crisil ESG 61' (Strong) for the Company based on the data pertaining to FY 2025-26.
Analysis Scores
Earnings Impact1/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating
Attachments (1)
📄pdf
Download →
AARTIDRUGS_08102026191926_AARTIDRUGS.pdf
View document text
Ref: ADL/SE/2026-27/53
October 8, 2026
To, To,
Listing/ Compliance Department Listing/ Compliance Department
BSE Limited National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1,
Dalal Street, G Block Bandra - Kurla Complex,
Mumbai – 400 001
Bandra (East), Mumbai – 400051
BSE CODE: 524348
NSE SYMBOL: AARTIDRUGS
Dear Sir/Madam,
Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure
Requirements) Regulations, 2015
Sub: Crisil ESG Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations,
2015, we would like to inform you that Crisil ESG Ratings & Analytic Limited (Crisil ESG Ratings),
a SEBI registered Category-1 ESG Rating Provider, vide its report received by the Company on
October 7, 2026, has assigned an Environmental, Social, and Governance (ESG) Rating of
‘Crisil ESG 61’ (Strong) for the Company based on the data pertaining to FY 2025-26.
Please note that the Company has not engaged Crisil ESG Ratings for ESG Rating. Crisil ESG
Ratings has independently prepared the report based on data pertaining to FY 2025-26 of the
Company available in public domain.
This disclosure is in compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure
Requirements) Regulations, 2015 read with the SEBI Circular SEBI/HO/49/14/14(7)2025-CFD-
POD2/I/3762/2026 dated January 30, 2026.
You are requested to take the same on records.
Thanking you,
Yours faithfully,
FOR AARTI DRUGS LIMITED
RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932